 The goal of this research study is to test the clinical effectiveness of a drug called infliximab Remicade in chronic beryllium disease CBD. This drug may reduce tumor necrosis factor-alpha TNF-a, which is associated with more severe disease and inflammation in the lung. Receiving infliximab may help with symptoms, and may improve clinical testing data normally ordered by your doctor, such as breathing tests. Baseline and follow-up testing will look for improvements in breathing tests pulmonary function testing, exchange of oxygen in the lungs exercise test, chest x ray, and lung inflammation. 